

Table S1: Geometric mean (geometric CV%) of eganelisib PK parameters in patients with solid tumors in the monotherapy cohort (Parts A and D)

Dose (mg)	Cycle (n)	C _{max} (µg/mL)	T _{max} ^a (hr)	AUC _{0-24hrs} (µg×hr/mL)	t _{1/2} (hr)	AR_C _{max}	AR_AUC _{0-24hrs}	C _{min} (µg/mL)	CL/F (L/hr)
10	1 (n=2-3)	0.310 (16.7)	2.00 (1-6)	5.21 (13.1)	39.8 (16.7)	-	-	-	-
	2 (n=2-3)	0.608 (38.2)	2.00 (1-6)	10.1 (24.7)	22.2 (49.1)	1.96 (21.7)	1.94 (18.7)	0.254 (30.4)	0.991 (24.7)
15	1 (n=3)	0.588 (23.6)	3.00 (2-3)	8.94 (24.7)	17.5 (20.7)	-	-	-	-
	2 (n=2)	1.05 (1.35)	1.50 (1-2)	16.3 (7.03)	19.2 (10.1)	2.04 (5.75)	2.10 (11.2)	0.431 (11.2)	0.918 (7.03)
20	1 (n=3)	0.754 (33.6)	2.00 (1-3)	11.3 (14.0)	18.0 (67.2)	-	-	-	-
	2 (n=1-3)	1.14 (14.7)	4.00 (2-6)	19.2 (30.4)	10.6 ^b	1.52 (24.6)	1.70 (30.8)	0.483 (65.9)	1.04 (30.4)
30	1 (n=3)	1.22 (36.8)	2.00 (1-2)	15.5 (52.6)	13.3 (36.7)	-	-	-	-
	2 (n=3)	2.21 (34.6)	1.00 (1-1)	22.0 (48.1)	15.3 (48.1)	1.81 (27.8)	1.42 (17.3)	0.405 (68.3)	1.36 (48.1)
40	1 (n=2-4)	1.90 (36.2)	3.00 (1-4)	28.9 (55.7)	16.2 (1.89)	-	-	-	-
	2 (n=1-2)	1.88 (108)	4.00 (2-6)	35.2 (78.2)	22.5 ^b	1.20 (68.7)	1.49 (48.7)	0.949 (95.9)	1.14 (78.2)
60	1 (n=18-22)	2.10 (39.3)	2.50 (1-6)	31.3 (47.6)	21.3 (51.0)	-	-	-	-
	2 (n=13-21)	3.21 (58.3)	3.00 (1-24)	45.5 (97.6)	23.6 (91.0)	1.67 (34.7)	1.75 (40.8)	1.41 ^c (96.4)	1.32 (97.6)

Abbreviations: AR, accumulation ratio; AUC_{0-24hrs}, area under the curve from time 0 to the last measurable concentration (AUC_{last}) up to 24 hours; CL/F, apparent clearance; C_{max}, maximum concentration; C_{min}, minimum concentration; CV, coefficient of variation; PK, pharmacokinetic; t_{1/2}, terminal half-life; T_{max}, time of maximum concentration.

^aMedian (range).

^bOnly 1 evaluable patient available for half-life calculation.

^cArithmetic mean (CV%) values are shown because there were individual C_{min} values being 0 and therefore, geometric mean (geometric CV%) could not be calculated.